Study of Cerebrolysin for Early Rehabilitation After Acute Ischemic Stroke with Moderate to Severe Neurological Impairment at University Medical Centre Ljubljana

What this Trial Is About

Researchers are evaluating the safety and effects of Cerebrolysin during early rehabilitation in patients with moderate to severe neurological impairment after an acute ischemic stroke. The study aims to determine how Cerebrolysin, given in addition to standard stroke care, impacts recovery and neurological outcomes at discharge and 90 days post-stroke. This research is conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, University Medical Centre Ljubljana, focusing on a specific patient group with NIHSS scores between 6 and 12. Patients in the study are divided into two groups one receiving Cerebrolysin plus standard care, and a control group receiving only standard treatment. Cerebrolysin is given as a 30 ml intravenous infusion daily for 10 consecutive days, diluted to 100 ml with saline and infused over 15 minutes. Both groups receive standard stroke treatments including reperfusion therapy, secondary prevention, and rehabilitation therapies like physiotherapy, occupational therapy, speech therapy, and neuropsychological assessments. Participants will be assessed using various tests and scales, including the Action Research Arm Test ARAT at 90 days post-stroke as the primary outcome. Additional evaluations include the NIH Stroke Scale, Modified Rankin Score, Extended Barthel Index, De Morton Mobility Index, and Montreal Cognitive Assessment at discharge and 90 days. The study monitors safety and treatment effects over this period, with participant involvement including clinical assessments and rehabilitation according to their needs.

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study